Author: McCreary, Erin K; Pogue, Jason M
Title: Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options Document date: 2020_3_23
ID: j0i9ozsz_45
Snippet: Patient populations who warrant therapy and the timing of initiation of therapy need to be defined. Given that disease progression can occur rapidly in stable patients and that viral loads are highest early in the infection course, the authors of this review opine that rapid initiation of therapy in high-risk populations (patients who are hospitalized or outpatients who are at high risk of complications) is rational and should be considered, idea.....
Document: Patient populations who warrant therapy and the timing of initiation of therapy need to be defined. Given that disease progression can occur rapidly in stable patients and that viral loads are highest early in the infection course, the authors of this review opine that rapid initiation of therapy in high-risk populations (patients who are hospitalized or outpatients who are at high risk of complications) is rational and should be considered, ideally in the context of a well-controlled, adequately powered trial. More important, however, this strategy is not without risk and needs to be weighed against potential adverse events (that remain poorly defined) and impending drug shortages with increases in use of these agents. To help address these concerns, careful consideration should be given to duration of therapy with many clinical trials and institutional protocols recommending 5-7 days for uncomplicated disease. Duration of therapy should be individualized to the patient and the progression of disease.
Search related documents:
Co phrase search for related documents- adverse event and careful consideration: 1
- adverse event and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adverse event and define need: 1, 2
- adverse event and disease progression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- adverse event and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adverse event and high risk population: 1, 2
- careful consideration and clinical trial: 1, 2
- careful consideration and concern address: 1
- careful consideration and disease progression: 1
- careful consideration and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- clinical trial and define need: 1, 2, 3
- clinical trial and disease progression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and disease progression patient: 1, 2, 3, 4, 5, 6
- clinical trial and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- complication high risk and disease progression: 1
- complication high risk and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- concern address and high risk: 1, 2
- define need and disease progression: 1, 2
- define need and disease progression patient: 1
Co phrase search for related documents, hyperlinks ordered by date